MOESM2 of Comparative analysis of chemical similarity methods for modular natural products with a hypothetical structure enumeration algorithm

Additional file 2: Fig. S1. Performance of individual chemical similarity methods on hypothetical libraries of linear peptides

Additional file 2: Table S2. of Global analysis of prokaryotic tRNA-derived cyclodipeptide biosynthesis

Active site residues annotated by Jacques et al... and predicted by PRISM. (XLSX 47 kb

Additional file 6: Figure S3. of Global analysis of prokaryotic tRNA-derived cyclodipeptide biosynthesis

Number of unique CDPS families discovered with cd-hit as a function of percent identity threshold. (PDF 4 kb

MOESM3 of Comparative analysis of chemical similarity methods for modular natural products with a hypothetical structure enumeration algorithm

Additional file 3: Fig. S2. Chemical similarity method performance on hypothetical libraries of linear hybrid natural products with and without starter units. (A) Trends in percentage of correct matches after substitution of a single monomer in a library of hypothetical linear hybrid natural products with starter units. (B) Percentage of correct matches with substitution of the starter unit or one to five non-starter unit monomers

Additional file 4: Table S3. of Global analysis of prokaryotic tRNA-derived cyclodipeptide biosynthesis

Complete set of 739 unique cyclodipeptide synthases identified in a global analysis of publicly available prokaryotic genomes. (XLSX 144 kb

Aminorifamycins and Sporalactams Produced in Culture by a Micromonospora sp. Isolated from a Northeastern-Pacific Marine Sediment Are Potent Antibiotics

The new ansa macrolide antibiotics <b>1</b> to <b>4</b> have been isolated from cultures of a <i>Micromonospora</i> sp. obtained from a marine sediment. Rifamycins <b>1</b> and <b>2</b> are the first natural ansa macrolides to have a 3-amino substituent. Sporalactams A (<b>3</b>) and B (<b>4</b>) are comprised of a heterocylic core <b>5</b> and a 14-membered ansa bridge that are both unprecedented. Sporalactam B (<b>4</b>) shows selective and potent inhibition of <i>Mycobacterium tuberculosis</i>